Current trends in electrospun nanofibers combined with mesenchymal stem cells for diabetic foot ulcer repair and regenerative therapy Authors: Hai Du, Xiaofan Yang, Zhenbing Chen Published: 2026 ABSTRACT SummaryDiabetic foot ulcer (DFU) is a common and clinically challenging chronic complication of diabetes, characterized by impaired healing, recurrent infections, and high amputation risk. Traditional treatments show limited efficacy in promoting neurovascular regeneration and tissue repair. In the field of tissue engineering, both electrospun nanofiber scaffolds and mesenchymal stem cells (MSCs) therapy have demonstrated considerable potential. Electrospun nanofibers closely imitate the structure and function of the native extracellular matrix (ECM). Furthermore, they can be functionally modified through directed strategies to incorporate antibacterial agents and various anti-inflammatory and pro-healing cytokines, thereby addressing multiple aspects of the DFU microenvironment. In contrast, MSCs play a crucial role in promoting wound healing owing to their paracrine signaling, immunomodulatory capabilities, and multidirectional differentiation potential. This review comprehensively summarizes the pathogenesis of DFU, the respective advantages of electrospun nanofibers and MSCs, and the latest research progress on their combined application for DFU treatment. Introduction In 2024, the global number of people aged 20–79 years with diabetes will reach 589 million, and this figure is projected to rise to 853 million by 2050.1,2 China has the highest number of people with diabetes (148 million).1 Diabetes-related lower extremity complications are significant and growing contributors to the global burden of disability. Approximately 19%–34% of diabetic patients develop a diabetic foot ulcer (DFU) during their lifetime, of whom about 20% require a lower extremity amputation.3 The wound, ischemia, and foot infection (WIfI) classification system is a method for assessing the risk of limb amputation in patients with DFU, primarily evaluating three aspects: the degree of tissue loss, ischemia, and foot infection (Figure 1).4 A meta-analysis showed that the one-year amputation rates for patients with WIfI stages of none, mild, moderate, and severe were 0%, 8%, 11%, and 38%, respectively.5 A meta-analysis of 34 studies involving 124,376 subjects demonstrated that DFU is associated with a high overall mortality, with a five-year rate approaching 50% and cardiovascular disease and infection being the two leading causes of mortality.6Figure 1Classification of ulcer in the diabetic foot WIfI system Classification of ulcer in the diabetic foot WIfI system DFU is a chronic complication of diabetes that frequently occurs in poorly managed cases. It is characterized by impaired healing of lower extremity wounds. In diabetes, impaired wound healing is characterized by reduced neovascularization and diminished recruitment of bone marrow-derived endothelial progenitor cells, along with decreased proliferation and migration of fibroblasts and keratinocytes.7 The mechanisms underlying impaired wound healing in patients with diabetes are highly complex and involve multiple contributing factors, such as angiopathy, neuropathy, and infection (Figure 2).Figure 2Pathophysiology of DFU involves ischemia, neuropathy, chronic inflammation, and infection Pathophysiology of DFU involves ischemia, neuropathy, chronic inflammation, and infection Current studies indicate that dysfunction exists in the microcirculatory system of patients with diabetes, primarily manifested as increased vascular permeability, impaired blood flow autoregulation, and decreased vascular tone.8 In patients with long-term poor glycemic control, the microcirculation can exhibit thickening of the capillary basement membrane and arteriolar hyalinosis, with the extent of thickening correlating with the level of glycemic control.9,10 Basement membrane thickening impairs nutrient exchange, hinders leukocyte migration, and reduces maximal hyperemic capacity (often reflecting diminished vasodilation reserve), leading to tissue ischemia and hypoxia. This ischemic and hypoxic state, in turn, elevates the levels of local reactive oxygen species (ROS). Additionally, diabetes can induce endothelial cell apoptosis through mechanisms such as chronic inflammation, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and impaired autophagy, ultimately resulting in delayed wound healing.11,12,13 Neuropathy is another major complication in patients with diabetes, affecting approximately 90% of individuals with DFU. Initial symptoms often present as glove- or stocking-like superficial sensory disturbances.14 Degeneration of C fibers and Aδ fibers is the primary mechanism underlying diabetic neuropathy, and the resulting sensory impairment further increases the risk of DFU development.15 These nerve fibers produce substance P (SP) and calcitonin gene-related peptide (CGRP), whose expression is regulated by nerve growth factor (NGF).16 SP and CGRP stimulate leukocyte chemotaxis and promote inflammatory cell infiltration, whereas CGRP enhances endothelial cell proliferation. These effects collectively facilitate the wound healing process. A study involving 18 patients with diabetic neuropathy and nine healthy controls showed that serum NGF levels were lower in the patient group, and the extent of NGF reduction was proportional to the decrease in nerve conduction velocity.17 In diabetic ulcers, infections can spread rapidly, leading to cellulitis and abscess formation, which are critical factors contributing to adverse outcomes such as gangrene and amputation. DFU is also accompanied by dysfunctional cellular activity in the wound bed. Wound healing is a complex process that comprises four phases: hemostasis, inflammation, proliferation, and remodeling. Macrophages play critical roles in wound healing, and their dysfunction is a major factor contributing to delayed DFU healing. Macrophages are broadly classified into M1 (pro-inflammatory) and M2 (anti-inflammatory and pro-repair) phenotypes, which serve as important sources of chemokines, matrix metalloproteinases (MMPs), and other inflammatory mediators in the body (Figure 3). Inflammatory monocytes and resident tissue macrophages exhibit key regulatory activities during tissue repair and fibrosis.18 During inflammation, circulating monocytes are recruited to injured tissues and differentiate into macrophages, which subsequently polarize into the M1 phenotype. As healing progresses, macrophages transition from the proinflammatory M1 phenotype to the anti-inflammatory and reparative M2 phenotype.19 M1 macrophages are capable of phagocytosing and clearing necrotic cells and debris and producing various pro-inflammatory mediators, such as TNF-α, IL-6, and IL-1β.20 In contrast, M2 macrophages express multiple growth factors, including transforming growth factor β (TGF-β) and vascular endothelial growth factor (VEGF), which facilitate inflammation resolution, tissue remodeling, and angiogenesis.21 Hyperglycemia impairs the macrophage phenotype transition from M1 to M2 phenotype, resulting in sustained M1 polarization.22 Consequently, DFU wounds remain in a chronic inflammatory milieu, further delaying the healing process. Fibroblasts in chronic wounds exhibit reduced expression of type 2 TGF-β receptors and demonstrate diminished proliferative responses to growth factors.23Figure 3Imbalanced macrophage polarization in DFU Imbalanced macrophage polarization in DFU Furthermore, studies have found that a high-glucose environment inhibits HIF-1, although the precise mechanism remains unclear.24 HIF-1, which modulates various biological processes by regulating hypoxia-inducible genes, is a master regulator of the hypoxic response. In DFU, the HIF-1 signaling pathway is suppressed, resulting in an impaired adaptive response to hypoxia and consequently delaying the healing process.7,25 Currently, DFU management primarily involves standard treatments recommended by most clinical practice guidelines, such as glycemic control, debridement, offloading, infection management, and revascularization. Although these approaches can create “opportunities” and “conditions” conducive to DFU healing, they are ineffective in adequately promoting vascular and neural regeneration, modulating the imbalanced inflammatory microenvironment, or reversing local cellular dysfunction. Consequently, even with standard treatment, DFU wounds remain refractory to healing and are associated with a high recurrence rate. This review discusses the advantages of electrospun nanofiber technology and stem cell-based therapy, as well as the promising application prospects of integrating these two innovative strategies for DFU treatment. Electrospun nanofibers Electrospinning technology, which utilizes high voltage to generate continuous ultrafine fibers from polymer solutions or melts, has evolved significantly since its early descriptions (Figure 4).26,27 Currently, electrospinning technology can be categorized into three primary types: uniaxial, coaxial, and multiaxial.27 Compared with uniaxial designs, coaxial and multi-axial configurations demonstrate a superior capability to retard and control the release of drug-loaded nanoparticles, thereby extending the duration of action and enhancing therapeutic efficacy.28,29 With the rapid advancement of technology, a variety of advanced electrospinning techniques have been developed, the details of which are summarized in Table 1.30 Furthermore, the advent of multifunctional portable electrospinning devices has significantly broadened application of electrospinning in tissue engineering.31 This technology is now widely applied in the biomedical field owing to its ability to produce nanofibers with high surface area-to-volume ratios and high porosity.32 Fibrillar collagen, the most abundant natural polymer in the body, constitutes a major ECM component, providing structural integrity and strength to tissues and creating a microenvironment essential for development and repair.33 Electrospun nanofibers resemble the architecture of the natural ECM, allowing them to elicit physiological and biochemical responses similar to those of the native matrix. This unique advantage has generated significant interest in the application of electrospun nanofibers for wound healing applications. By selecting different polymers, adjusting processing parameters (such as voltage and flow rate), and designing specialized collectors, electrospinning enables precise control over fiber diameter, orientation, porosity, and surface morphology to meet diverse biological functional requirements.34Figure 4Schematic illustration of electrospinning techniques(A) Conventional uniaxial electrospinning. A polymer solution is extruded through a spinneret under high voltage, forming a Taylor cone and generating nanofibers collected on a grounded collector.(B) Coaxial electrospinning. A dual-capillary system enables the fabrication of core-shell nanofibers by simultaneously ejecting core and shell solutions.(C) Side-by-side electrospinning. Two immiscible solutions are electrospun alongside each other, producing Janus-type nanofibers.(D) Dual-nozzle electrospinning. Separate nozzles eject different polymer solutions to create hybrid nanofiber mats composed of distinct fiber types.(E) Aligned electrospinning. The incorporation of auxiliary electrodes or a high-speed rotating collector aligns nanofibers uniaxially.(F) Yarn electrospinning. Conjugated electrospinning with oppositely charged nozzles and a rotating funnel collector produces continuous nanofiber yarns.(G) Roll-to-roll electrospinning. A multi-nozzle array combined with a continuously moving collector enables scalable, high-throughput production of uniform nanofiber membranes.Table 1Summary of advanced electrospinning techniquesTechniqueDescriptionKey characteristicsApplicationsCoaxial electrospinningFabricates core-shell nanofibers using a dual-capillary system; inner nozzle ejects core material, outer nozzle dispenses shell materialPrecise control over material distribution; distinct core-shell morphology; governed by flow rates, viscosities, and surface tensionsDrug delivery with controlled release; encapsulationSide-by-Side electrospinningFabricates Janus nanofibers using a modified coaxial setup; two immiscible solutions flow alongside each other without mixingAsymmetric, anisotropic material distribution; lateral separation via symmetry-breaking mechanismsDual-responsive sensors; selective filtration; multifunctional devicesDual-nozzle electrospinningCreates hybrid nanofiber mats composed of distinct fibers from separate nozzles; combines materials with contrasting propertiesIndependent fiber deposition; flexible integration of hydrophobic/hydrophilic or complementary polymersMultifunctional membranes; advanced filtration; functional coatingsAligned electrospinningProduces uniaxially aligned nanofibers via electric field modulation using insulating blocks; single-nozzle systemLarge-area alignment (>20 × 20 cm2); cross-aligned or rhombus-like patterns; 2D wave-like jet motion; high porosity and optical uniformityEnergy systems (batteries, supercapacitors); optical membranes; mechanically stable scaffoldsYarn electrospinningProduces continuous nanofiber yarns via conjugated electrospinning with oppositely charged nozzles and a rotating collectorCore-spun, coreless, and dual-electrospun yarns; controlled twisting; enhanced tensile strength and structural integritySmart textiles; wearable sensors; energy harvesting; piezoelectric devicesRoll-to-roll electrospinning with multi-nozzleIntegrates multi-nozzle array with a continuously moving collector for high-throughput, continuous membrane productionScalable, continuous fabrication; multilayered dual nanofibers; precise control over alignment and diameter via electric field modulationIndustrial-scale membrane manufacturing; large-area uniform coatings; high-performance functional membranes Schematic illustration of electrospinning techniques (A) Conventional uniaxial electrospinning. A polymer solution is extruded through a spinneret under high voltage, forming a Taylor cone and generating nanofibers collected on a grounded collector. (B) Coaxial electrospinning. A dual-capillary system enables the fabrication of core-shell nanofibers by simultaneously ejecting core and shell solutions. (C) Side-by-side electrospinning. Two immiscible solutions are electrospun alongside each other, producing Janus-type nanofibers. (D) Dual-nozzle electrospinning. Separate nozzles eject different polymer solutions to create hybrid nanofiber mats composed of distinct fiber types. (E) Aligned electrospinning. The incorporation of auxiliary electrodes or a high-speed rotating collector aligns nanofibers uniaxially. (F) Yarn electrospinning. Conjugated electrospinning with oppositely charged nozzles and a rotating funnel collector produces continuous nanofiber yarns. (G) Roll-to-roll electrospinning. A multi-nozzle array combined with a continuously moving collector enables scalable, high-throughput production of uniform nanofiber membranes. Table 1Summary of advanced electrospinning techniquesTechniqueDescriptionKey characteristicsApplicationsCoaxial electrospinningFabricates core-shell nanofibers using a dual-capillary system; inner nozzle ejects core material, outer nozzle dispenses shell materialPrecise control over material distribution; distinct core-shell morphology; governed by flow rates, viscosities, and surface tensionsDrug delivery with controlled release; encapsulationSide-by-Side electrospinningFabricates Janus nanofibers using a modified coaxial setup; two immiscible solutions flow alongside each other without mixingAsymmetric, anisotropic material distribution; lateral separation via symmetry-breaking mechanismsDual-responsive sensors; selective filtration; multifunctional devicesDual-nozzle electrospinningCreates hybrid nanofiber mats composed of distinct fibers from separate nozzles; combines materials with contrasting propertiesIndependent fiber deposition; flexible integration of hydrophobic/hydrophilic or complementary polymersMultifunctional membranes; advanced filtration; functional coatingsAligned electrospinningProduces uniaxially aligned nanofibers via electric field modulation using insulating blocks; single-nozzle systemLarge-area alignment (>20 × 20 cm2); cross-aligned or rhombus-like patterns; 2D wave-like jet motion; high porosity and optical uniformityEnergy systems (batteries, supercapacitors); optical membranes; mechanically stable scaffoldsYarn electrospinningProduces continuous nanofiber yarns via conjugated electrospinning with oppositely charged nozzles and a rotating collectorCore-spun, coreless, and dual-electrospun yarns; controlled twisting; enhanced tensile strength and structural integritySmart textiles; wearable sensors; energy harvesting; piezoelectric devicesRoll-to-roll electrospinning with multi-nozzleIntegrates multi-nozzle array with a continuously moving collector for high-throughput, continuous membrane productionScalable, continuous fabrication; multilayered dual nanofibers; precise control over alignment and diameter via electric field modulationIndustrial-scale membrane manufacturing; large-area uniform coatings; high-performance functional membranes Summary of advanced electrospinning techniques Antibacterial activity Electrospun nanofibers can be functionalized with various antibacterial agents—including silver nanoparticles (AgNPs), antibiotics (e.g., levofloxacin, vancomycin, etc.), and antimicrobial peptides—to combat infection in DFU. Once released into the surrounding environment, AgNPs bind to free sulfhydryl groups on bacterial surfaces, inactivating phosphomannose isomerase and disrupting the bacterial metabolic processes. Consequently, AgNPs are widely recognized as highly effective antimicrobial agents.35 Murillo et al. demonstrated that hybrid electrospun nanofibers incorporating AgNPs exhibited significantly enhanced antifungal efficacy compared to other nanofiber formulations.36 Monavari et al. developed a novel core-shell nanofiber-based dressing for burn wounds, in which levofloxacin and quercetin were incorporated into the core and shell regions, respectively. This dressing promoted faster burn wound healing compared to sterile gauze.37 Raghunathan et al. found that incorporating microalgal peptides into a blend of polycaprolactone (PCL) and ƙ-carrageenan (ƙ-C) resulted in nanofibers that exhibited antibacterial activity and significantly enhanced wound healing properties.38 Promoting angiogenesis Ischemia and hypoxia are major factors contributing to delayed healing in DFU. An adequate blood supply is essential for delivering nutrients and supporting tissue regeneration. Vasculogenesis and angiogenesis play critical roles in development and subsequent physiological homeostasis. VEGF is a potent proangiogenic growth factor. It regulates the activity of multiple kinases through the classical VEGF signaling pathway (via VEGFR-1 and VEGFR-2), ultimately promoting cell proliferation, migration, survival, and vascular permeability during angiogenesis and vascular formation.39,40 Tavakoli et al. showed that wound dressings made from VEGF-loaded electrospun nanofibers significantly accelerated wound closure, vascularization, collagen synthesis, and epidermal regeneration.41 Another growth factor, basic fibroblast growth factor (bFGF), also mediates angiogenesis and plays a crucial role in the embryonic development and differentiation of various connective tissues.42 Lee et al. demonstrated that electrospun nanofibers incorporating bFGF promoted bone regeneration.43 In the near future, such nanofibers may be applied to improve wound healing in DFU. Promoting neural regeneration NGF and brain-derived neurotrophic factor (BDNF) were among the first neurotrophic factors to be discovered and remain two crucial members of the neurotrophin family. They play key roles in nervous system development, neuronal survival, differentiation, axonal guidance, and synaptic plasticity.44 Studies have shown that the expression levels of NGF are significantly reduced in patients with diabetes.45 Neural damage induced by diabetes is a major factor in the development and progression of DFU, making the promotion of neural regeneration and repair an essential aspect of DFU treatment. Chang et al. developed electrospun nanofibers incorporated with two neurotrophic factors (NGF and BDNF). The results demonstrated that NGF increased the density of neural stem cells and significantly promoted axonal elongation, whereas BDNF markedly enhanced myelination.46 Notably, one study indicated that an NGF concentration gradient can guide directional neuronal growth, whereas a uniform NGF concentration does not produce this effect.47 These findings suggest that the ability of NGF to promote neural regeneration is closely associated with its concentration gradient. In recent years, nanofiber scaffolds based on biocompatible conductive polymers, such as polypyrrole (PPy), have shown considerable potential in tissue engineering. PPy modulates various cellular activities, including DNA synthesis, cell migration, and proliferation, and significantly enhances the expression and secretion of neurotrophic factors, such as NGF and BDNF.48,49 Leveraging the hydrophilicity of chitosan (CS) and the conductivity of PPy, Sadeghi et al. developed an electrospun nanofibrous composite scaffold composed of poly(ε-caprolactone) (PCL), CS, and PPy. Their results revealed that this nanofibrous scaffold significantly increased the proliferation rate of PC12 cells (by up to 356%) and promoted axonal extension in PC12 neurons.50 Modulating the immune microenvironment Studies have indicated that an imbalance in macrophage polarization is a critical factor contributing to impaired wound healing in DFU. Consequently, strategies that utilize electrospun nanofibers to correct this polarization imbalance have garnered increasing research interest. In a study by Zamani et al., RAW264.7 macrophages cultured on electrospun nanofiber mats containing 20 wt. % emu oil (a natural anti-inflammatory substance) successfully repolarized from the M1 to the M2 phenotype, accompanied by significantly reduced expression levels of IL-6, IL-1β, and TNF-α.51 In another study, the anti-inflammatory drug asiaticoside (AS) was incorporated into electrospun nanofibers. The results demonstrated a marked reduction in inflammatory cell infiltration at the implantation site, specifically a decrease in M1 macrophage infiltration and an increase in M2 macrophage presence.52 These findings suggest that delivering anti-inflammatory agents via electrospun nanofibers can effectively promote the transition of macrophages from the M1 to M2 phenotype. However, further evidence is required before these fibrous scaffolds can be applied clinically. Mesenchymal stem cells MSCs are multipotent cells capable of differentiating into both mesenchymal and non-mesenchymal lineages in vitro and in vivo, and are present in almost all organs and tissues.53 One of the most notable characteristics of MSCs is their ability to differentiate into adipocytes, chondrocytes, and osteoblasts in vitro. MSCs not only exhibit low immunogenicity, making them suitable for allogeneic transplantation, but also exert immunosuppressive effects post-implantation. Consequently, they have been widely used in regenerative medicine, particularly MSCs derived from bone marrow and adipose tissue (Figure 5).54Figure 5The main sources and biological functions of MSCs in the tissue engineering The main sources and biological functions of MSCs in the tissue engineering Paracrine, immunomodulatory, and anti-inflammatory effects Accumulating evidence demonstrates that MSCs facilitate wound closure primarily through paracrine signaling, secreting a repertoire of cytokines that are crucial for tissue repair. Nakamura et al. transfected rat bone marrow-derived MSCs with plasmid DNA encoding stromal cell-derived factor-1 (SDF-1). Subsequent cell migration assays demonstrated that the transfected MSCs not only significantly enhanced the migration of both MSCs and dermal fibroblasts but also markedly increased the secretion levels of VEGF, hepatocyte growth factor (HGF), and interleukin-6 (IL-6).55 Exosomes secreted by MSCs have also attracted considerable attention in tissue engineering. Exosomes are membrane-bound extracellular vesicles with diameters ranging from 30 to 200 nm, secreted by various cell types. They play important roles in intercellular communication by carrying diverse proteins, lipids, and RNAs.56 Shabbir et al. found that MSC-derived exosomes significantly activated multiple intracellular signaling pathways (including AKT, ERK 1/2, and STAT3), thereby inducing the expression of genes involved in cell cycle progression and the production of various growth factors known to be critical in wound healing.57 Thus, MSCs can modulate the activation, migration, and proliferation of different cell types to facilitate wound healing. This paracrine/vesicular mechanism enables MSCs to remotely modulate the activity, migration, and proliferation of various resident wound cells, including fibroblasts, keratinocytes, and endothelial cells, thereby accelerating healing. Beyond direct tissue repair, MSC-derived exosomes exert potent immunomodulatory effects, notably by reprogramming macrophage polarization and suppressing inflammation. In a study by Lo Sicco et al., exosomes isolated from human adipose tissue-derived MSCs promoted macrophage proliferation and polarization, with these effects being more pronounced under hypoxic conditions.58 Another study showed that the extracellular vesicles of MSCs induced high expression levels of anti-inflammatory transcripts (e.g., IL-10, TGFB1), while significantly reducing pro-inflammatory ones (e.g., L-1B, IL-6, TNFA, and IL-12P40).59 The same study also reported an increase in the population of regulatory T cells (Tregs) following treatment with MSCs extracellular vesicles.59 Tregs possess immunosuppressive functions and help maintain immune homeostasis by suppressing pro-inflammatory responses and limiting excessive immune activation. MSCs delivery strategies Although stem cell therapy holds significant therapeutic potential, the precise delivery and maintenance of the viability of MSCs within the challenging microenvironment of diabetic ulcers, characterized by persistent ischemia, hypoxia, and inflammation, remains a major challenge. Conventional methods for delivery strategies of MSCs, such as systemic intravenous injection or local administration, are limited by poor cell persistence and low engraftment efficiency.60 Clinical studies investigating MSC-based treatments for DFU are summarized in Table 2.61,62,63,64,65,66,67 However, those clinical evidences for MSCs therapy in DFU is inherently limited. The generalizability and robustness of findings are compromised by small cohorts, heterogeneity among participants and MSCs preparations, variable follow-up, and often inadequate study designs lacking proper controls or blinding. Several strategies have been proposed to overcome these limitations, including the design of protective or bioactive carriers and cell engineering.Table 2Summary of clinical studies on MSC-based therapy for DFUAuthorMSCs sourceDFU patientsAdministration routeFollow-up periodPrimary outcomesZhang et al.HUC-MSC14Local and intravenous administration3 yearsThe ulcers significantly improved, and no amputations were performed. Two cases of transient fever were reportedAndersen, et al.BM-MSC2Local administration24 monthsThe ulcer size was reduced, but complete healing was not achieved. Increased wound exudation was observedLu et al.BM-MSC41Intramuscular or ulcer base injection3 yearsReduced rates of ulcer recurrence and amputationsQin HL et al.HUC-MSC53Intravascular infusion and perilesional injection around the foot ulcer following angioplasty3 monthsUlcers significantly improved, with some achieving complete healingMoon KC et al.HUC-MSC59Local administration12 weeksAccelerated ulcer healing ratesKerstan et al.ABCB5+MSC23Local administration12 weeksUlcers significantly improved, with some achieving complete healingProcházka et al.BM-MSC96Local administration4 monthsThe limb salvage rate was 79%Abbreviation, HUC-MSC, Human umbilical cord mesenchymal stem cells; BM-MSC, bone marrow-derived mesenchymal stem cell; ABCB5+MSC, ATP-binding cassette subfamily B member 5 positive mesenchymal stromal cell. Table 2Summary of clinical studies on MSC-based therapy for DFUAuthorMSCs sourceDFU patientsAdministration routeFollow-up periodPrimary outcomesZhang et al.HUC-MSC14Local and intravenous administration3 yearsThe ulcers significantly improved, and no amputations were performed. Two cases of transient fever were reportedAndersen, et al.BM-MSC2Local administration24 monthsThe ulcer size was reduced, but complete healing was not achieved. Increased wound exudation was observedLu et al.BM-MSC41Intramuscular or ulcer base injection3 yearsReduced rates of ulcer recurrence and amputationsQin HL et al.HUC-MSC53Intravascular infusion and perilesional injection around the foot ulcer following angioplasty3 monthsUlcers significantly improved, with some achieving complete healingMoon KC et al.HUC-MSC59Local administration12 weeksAccelerated ulcer healing ratesKerstan et al.ABCB5+MSC23Local administration12 weeksUlcers significantly improved, with some achieving complete healingProcházka et al.BM-MSC96Local administration4 monthsThe limb salvage rate was 79%Abbreviation, HUC-MSC, Human umbilical cord mesenchymal stem cells; BM-MSC, bone marrow-derived mesenchymal stem cell; ABCB5+MSC, ATP-binding cassette subfamily B member 5 positive mesenchymal stromal cell. Summary of clinical studies on MSC-based therapy for DFU Abbreviation, HUC-MSC, Human umbilical cord mesenchymal stem cells; BM-MSC, bone marrow-derived mesenchymal stem cell; ABCB5+MSC, ATP-binding cassette subfamily B member 5 positive mesenchymal stromal cell. Protective carriers can provide a shielded microenvironment for MSCs, insulating them from the damaging pathological milieu. For example, autologous platelet-rich fibrin (PRF) has been used to encapsulate MSCs, providing a fibrin-based protective barrier against ROS-induced damage.68 A microneedle array system composed of a poly(lactic-co-glycolic acid) (PLGA) shell and gelatin methacryloyl-MSC mixture has also been developed for enhanced MSCs delivery.69 Additionally, a tunable hydrogel system was designed to control degradation rates by adjusting the ester and amide bond ratios, thereby improving MSCs retention and persistence.70 In recent years, decellularized extracellular matrix (dECM) has gained significant attention as a novel bioactive carrier. It preserves crucial biochemical cues for cell adhesion, proliferation, and differentiation, effectively mimicking the native tissue microenvironment.71 For instance, a decellularized human placental sponge, characterized by a low degradation rate and favorable mechanical properties, has been shown to significantly accelerate wound healing when seeded with MSCs.27 Additionally, dECM can enhance the paracrine function of MSCs, a feature that may also serve as a useful pretreatment strategy.72 Cell engineering focuses on genetically or functionally modifying MSCs to confer enhanced targetability, survival, or specific secretory capabilities. One approach involves engineering enucleated bone marrow-derived MSCs through mRNA transfection to enable sustained secretion of IL-4, thereby promoting macrophage polarization toward the regenerative M2 phenotype.73 Combined strategies of electrospun nanofibers and MSCs Electrospun nanofibers offer versatile functionalization capabilities, while MSCs provide potent biological activity. Both have been extensively investigated for treating DFU. In recent years, growing attention has been directed toward combining of these two technologies for enhanced therapeutic outcomes. Nanofiber scaffolds can be pre-functionalized and loaded with MSCs to create synergistic biological effects on the host. Compared to conventional hydrogels, electrospun nanofiber scaffolds better mimic the native ECM and provide adequate mechanical support, thereby offering a favorable microenvironment for MSCs adhesion, colonization, and survival. In turn, MSCs secrete various bioactive cytokines. Together, they collectively regulate the wound microenvironment to promote neurovascular regeneration. Current studies utilizing electrospun nanofiber scaffolds loaded with MSCs to enhance diabetic wound healing are summarized in Table 3.74,75,76,77,78,79,80,81,82,83,84Table 3Summary of studies on electrospun nanofiber-laden MSCs for diabetic wound therapyAuthorMSCs sourceFabrication of nanoscaffoldsPrimary outcomesGao et al.BM-MSCsScaffolds modified with membranes from LPS/IFN-γ-activated murine RAW264.7 cells1.Enhanced antioxidant stress capacity of MSCs.2.Accelerated wound healing accompanied by rapid re-epithelialization and increased neovascularization.3.Reduced inflammatory response in the wound.Chen et al.BM-MSCstransforms 2D nanofiber mats into once-inaccessible 3D scaffolds with predesigned complex shapes1.The wound exhibited abundant dense granulation tissue formation and achieved complete re-epithelialization.2.A significant increase in the M2/M1 macrophage ratio was observed.3.Expression of pro-inflammatory cytokines decreased, while expression of anti-inflammatory cytokines increased.Prakashan et al.BM-MSCsNanoscaffolds composed of PCL and gelatin1.Confirmed chondrogenic, osteogenic, and adipogenic differentiation of MSCs within the scaffold.2.Improved proliferation rate of BMSCs (bone marrow-derived mesenchymal stem cells).3.Significant wound healing efficacy was achieved, with morphology closely resembling normal skin.Assani KD et al.AD-MSCsFabrication of fiber scaffolds using Pullulan and gelatin loaded with RAInduce macrophage polarization from the M1 to the M2 phenotype.Duan et al.BM-MSCsNanoscaffolds composed of euphorbia hirta extract, PCL, and collagen1.Enhanced the ability to prevent bacterial ingrowth.2.Significantly promoted epidermal proliferation and increased the wound closure rate.Plascencia et al.AD-MSCsFabrication of fiber scaffolds using gelatin, PLA, and aloe vera mucilage loaded with tetracycline hydrochloride1.Strengthened antibacterial activity against Staphylococcus aureus.2.Facilitated the proliferation of dermal fibroblasts.AuthorMSCs sourceFabrication of nanoscaffoldsPrimary outcomesAmiri et al.AD-MSCsFabrication of nanoscaffolds composed of using silk fibroin, chitosan, and ZnO loaded with AST1.Maintained the proliferative activity of MSCs.2.The fibrous scaffold exhibited antibacterial properties and pro-angiogenic potential.3.The incorporation of AST enhanced the scaffold’s performance in wound healing in diabetic mice.Shen et al.NT-3-stimulated BM-MSCsNanoscaffolds composed of PLA, mixed silk, and collagen1.NT-3 promotes MSC proliferation and migration.2.Promotes vascular regeneration and accelerates diabetic foot wound healing.He et al.BDNF-stimulated BM-MSCsNanoscaffolds composed of PLA, silk, and collagen1.Can induce the differentiation of MSCs into endothelial cells.2.Promotes angiogenesis and healing of diabetic ulcers.Mirzadegan et al.MenSCsNanoscaffolds composed of amniotic membrane and silk fibroin1.A significant increase in M2 macrophages was observed.2.Promotes neovascularization and wound healing.3.Gene expression of various healing markers was significantly upregulated.Chen et al.UC-MSCsFabrication of fiber scaffolds using PCL and gelatin loaded with curcumin1.The expression of VEGF and IGF genes was significantly increased.2.Possesses antioxidant stress and antibacterial activity.3.The wound closure rate was significantly higher than that of the control group, accompanied by reduced inflammation.Abbreviation, BM-MSCs, bone marrow-derived mesenchymal stem cells; AD-MSCs, adipose-derived mesenchymal stem cells; LPS, lipopolysaccharide; IFN-γ, Interferon-gamma; PCL: poly-ε-caprolactone. RA, retinoic acid; PLA, polylactic acid;AST, astragalus arbusculinus; NT-3, neurotrophin-3; BDNF, brain-derived neurotrophic factor; MenSCs, menstrual blood-derived mesenchymal stem cells; UC-MSCs, Umbilical cord-derived mesenchymal stem cells; VEGF, vascular endothelial growth factor; IGF, insulin like growth factor. Table 3Summary of studies on electrospun nanofiber-laden MSCs for diabetic wound therapyAuthorMSCs sourceFabrication of nanoscaffoldsPrimary outcomesGao et al.BM-MSCsScaffolds modified with membranes from LPS/IFN-γ-activated murine RAW264.7 cells1.Enhanced antioxidant stress capacity of MSCs.2.Accelerated wound healing accompanied by rapid re-epithelialization and increased neovascularization.3.Reduced inflammatory response in the wound.Chen et al.BM-MSCstransforms 2D nanofiber mats into once-inaccessible 3D scaffolds with predesigned complex shapes1.The wound exhibited abundant dense granulation tissue formation and achieved complete re-epithelialization.2.A significant increase in the M2/M1 macrophage ratio was observed.3.Expression of pro-inflammatory cytokines decreased, while expression of anti-inflammatory cytokines increased.Prakashan et al.BM-MSCsNanoscaffolds composed of PCL and gelatin1.Confirmed chondrogenic, osteogenic, and adipogenic differentiation of MSCs within the scaffold.2.Improved proliferation rate of BMSCs (bone marrow-derived mesenchymal stem cells).3.Significant wound healing efficacy was achieved, with morphology closely resembling normal skin.Assani KD et al.AD-MSCsFabrication of fiber scaffolds using Pullulan and gelatin loaded with RAInduce macrophage polarization from the M1 to the M2 phenotype.Duan et al.BM-MSCsNanoscaffolds composed of euphorbia hirta extract, PCL, and collagen1.Enhanced the ability to prevent bacterial ingrowth.2.Significantly promoted epidermal proliferation and increased the wound closure rate.Plascencia et al.AD-MSCsFabrication of fiber scaffolds using gelatin, PLA, and aloe vera mucilage loaded with tetracycline hydrochloride1.Strengthened antibacterial activity against Staphylococcus aureus.2.Facilitated the proliferation of dermal fibroblasts.AuthorMSCs sourceFabrication of nanoscaffoldsPrimary outcomesAmiri et al.AD-MSCsFabrication of nanoscaffolds composed of using silk fibroin, chitosan, and ZnO loaded with AST1.Maintained the proliferative activity of MSCs.2.The fibrous scaffold exhibited antibacterial properties and pro-angiogenic potential.3.The incorporation of AST enhanced the scaffold’s performance in wound healing in diabetic mice.Shen et al.NT-3-stimulated BM-MSCsNanoscaffolds composed of PLA, mixed silk, and collagen1.NT-3 promotes MSC proliferation and migration.2.Promotes vascular regeneration and accelerates diabetic foot wound healing.He et al.BDNF-stimulated BM-MSCsNanoscaffolds composed of PLA, silk, and collagen1.Can induce the differentiation of MSCs into endothelial cells.2.Promotes angiogenesis and healing of diabetic ulcers.Mirzadegan et al.MenSCsNanoscaffolds composed of amniotic membrane and silk fibroin1.A significant increase in M2 macrophages was observed.2.Promotes neovascularization and wound healing.3.Gene expression of various healing markers was significantly upregulated.Chen et al.UC-MSCsFabrication of fiber scaffolds using PCL and gelatin loaded with curcumin1.The expression of VEGF and IGF genes was significantly increased.2.Possesses antioxidant stress and antibacterial activity.3.The wound closure rate was significantly higher than that of the control group, accompanied by reduced inflammation.Abbreviation, BM-MSCs, bone marrow-derived mesenchymal stem cells; AD-MSCs, adipose-derived mesenchymal stem cells; LPS, lipopolysaccharide; IFN-γ, Interferon-gamma; PCL: poly-ε-caprolactone. RA, retinoic acid; PLA, polylactic acid;AST, astragalus arbusculinus; NT-3, neurotrophin-3; BDNF, brain-derived neurotrophic factor; MenSCs, menstrual blood-derived mesenchymal stem cells; UC-MSCs, Umbilical cord-derived mesenchymal stem cells; VEGF, vascular endothelial growth factor; IGF, insulin like growth factor. Summary of studies on electrospun nanofiber-laden MSCs for diabetic wound therapy 1.Enhanced antioxidant stress capacity of MSCs. Enhanced antioxidant stress capacity of MSCs. 2.Accelerated wound healing accompanied by rapid re-epithelialization and increased neovascularization. Accelerated wound healing accompanied by rapid re-epithelialization and increased neovascularization. 3.Reduced inflammatory response in the wound. Reduced inflammatory response in the wound. 1.The wound exhibited abundant dense granulation tissue formation and achieved complete re-epithelialization. The wound exhibited abundant dense granulation tissue formation and achieved complete re-epithelialization. 2.A significant increase in the M2/M1 macrophage ratio was observed. A significant increase in the M2/M1 macrophage ratio was observed. 3.Expression of pro-inflammatory cytokines decreased, while expression of anti-inflammatory cytokines increased. Expression of pro-inflammatory cytokines decreased, while expression of anti-inflammatory cytokines increased. 1.Confirmed chondrogenic, osteogenic, and adipogenic differentiation of MSCs within the scaffold. Confirmed chondrogenic, osteogenic, and adipogenic differentiation of MSCs within the scaffold. 2.Improved proliferation rate of BMSCs (bone marrow-derived mesenchymal stem cells). Improved proliferation rate of BMSCs (bone marrow-derived mesenchymal stem cells). 3.Significant wound healing efficacy was achieved, with morphology closely resembling normal skin. Significant wound healing efficacy was achieved, with morphology closely resembling normal skin. 1.Enhanced the ability to prevent bacterial ingrowth. Enhanced the ability to prevent bacterial ingrowth. 2.Significantly promoted epidermal proliferation and increased the wound closure rate. Significantly promoted epidermal proliferation and increased the wound closure rate. 1.Strengthened antibacterial activity against Staphylococcus aureus. Strengthened antibacterial activity against Staphylococcus aureus. 2.Facilitated the proliferation of dermal fibroblasts. Facilitated the proliferation of dermal fibroblasts. 1.Maintained the proliferative activity of MSCs. Maintained the proliferative activity of MSCs. 2.The fibrous scaffold exhibited antibacterial properties and pro-angiogenic potential. The fibrous scaffold exhibited antibacterial properties and pro-angiogenic potential. 3.The incorporation of AST enhanced the scaffold’s performance in wound healing in diabetic mice. The incorporation of AST enhanced the scaffold’s performance in wound healing in diabetic mice. 1.NT-3 promotes MSC proliferation and migration. NT-3 promotes MSC proliferation and migration. 2.Promotes vascular regeneration and accelerates diabetic foot wound healing. Promotes vascular regeneration and accelerates diabetic foot wound healing. 1.Can induce the differentiation of MSCs into endothelial cells. Can induce the differentiation of MSCs into endothelial cells. 2.Promotes angiogenesis and healing of diabetic ulcers. Promotes angiogenesis and healing of diabetic ulcers. 1.A significant increase in M2 macrophages was observed. A significant increase in M2 macrophages was observed. 2.Promotes neovascularization and wound healing. Promotes neovascularization and wound healing. 3.Gene expression of various healing markers was significantly upregulated. Gene expression of various healing markers was significantly upregulated. 1.The expression of VEGF and IGF genes was significantly increased. The expression of VEGF and IGF genes was significantly increased. 2.Possesses antioxidant stress and antibacterial activity. Possesses antioxidant stress and antibacterial activity. 3.The wound closure rate was significantly higher than that of the control group, accompanied by reduced inflammation. The wound closure rate was significantly higher than that of the control group, accompanied by reduced inflammation. Abbreviation, BM-MSCs, bone marrow-derived mesenchymal stem cells; AD-MSCs, adipose-derived mesenchymal stem cells; LPS, lipopolysaccharide; IFN-γ, Interferon-gamma; PCL: poly-ε-caprolactone. RA, retinoic acid; PLA, polylactic acid;AST, astragalus arbusculinus; NT-3, neurotrophin-3; BDNF, brain-derived neurotrophic factor; MenSCs, menstrual blood-derived mesenchymal stem cells; UC-MSCs, Umbilical cord-derived mesenchymal stem cells; VEGF, vascular endothelial growth factor; IGF, insulin like growth factor. Materials used in electrospun nanofiber scaffolds The selection of materials is fundamental to constructing efficient cell-scaffold complexes, with the core principle being to balance biocompatibility, mechanical properties, and biofunctionality. Several materials have been widely used in the fabrication of nanofiber scaffolds, including PCL, PLGA, polyvinyl alcohol (PVA), and CS. PCL, a semi-crystalline linear aliphatic polyester, is an FDA-approved synthetic polymer widely used in tissue engineering due to its favorable properties.85 It exhibits high tensile strength, toughness, and ductility, providing long-term mechanical support to prevent the collapse of newly formed tissues during wound healing.86 PCL is biocompatible and degrades slowly via hydrolysis of ester bonds and phagocytosis, ultimately being metabolized into non-toxic products.87,88 Although its slow degradation rate (ranging from several months to years) helps maintain structural integrity during tissue regeneration, the hydrophobic surface of PCL limits cell adhesion, potentially impairing MSCs attachment, proliferation, and function. To address this, blending with natural polymers such as gelatin, CS, or collagen is commonly employed to introduce hydrophilicity and cell-recognition motifs. For instance, Prakashan et al. demonstrated that PCL-gelatin hybrid scaffolds significantly enhanced the adhesion and proliferation of BM-MSCs.76 PLGA, a random copolymer of PLA and PGA, offers tunable mechanical properties and degradation rates. Ramdhanie et al. reported that PLGA fiber scaffolds (fiber diameter: 0.9–1.3 μm) exhibited mechanical properties similar to those of natural soft tissues, with fiber orientation and the PLA/PGA ratio being key determinants.89 While pure PGA degrades within weeks under physiological conditions—a rate too rapid for DFU healing—PLGA allows for adjustable degradation kinetics. The degradation of PLGA can be decelerated by reducing the glycolic acid content and increasing the molecular weight.90 However, the poor water solubility of PLGA may hinder its performance in DFU wounds. Given the variability in healing periods among patients, fine-tuning the degradation profile of PLGA scaffolds to match individual healing timelines remains necessary. PVA, a degradable synthetic polymer obtained through hydrolysis (alcoholysis) of polyvinyl acetate, is characterized by high hydrophilicity and water solubility. It is often used to improve the mechanical properties, biodegradability, biocompatibility, and processability of other polymers in electrospinning.91 Its water-absorbing and swelling properties make it suitable for managing exudate in diabetic wounds. However, uncrosslinked PVA scaffolds disintegrate in aqueous environments, limiting their structural stability. To enhance stability, PVA is often blended with materials such as silk fibroin or AgNPs.92,93 Koosha et al. demonstrated that a CS/PVA (30/70) nanofibrous scaffold promoted fibroblast attachment and proliferation without cytotoxicity.94 CS, a natural linear polysaccharide derived from the deacetylation of chitin, structurally resembles glycosaminoglycans in the extracellular matrix and exhibits inherent antibacterial and antifungal activities.95,96,97 These properties make it advantageous for DFU management. However, CS suffers from poor water solubility and inadequate mechanical strength. Common modification strategies include blending with AgNPs to enhance mechanical properties,98 incorporating coumaric acid (p-CA) to improve solubility and antioxidant activity,97 and grafting quaternary ammonium groups to strengthen antibacterial efficacy.99 Sources and limitations of MSCs MSCs used in tissue engineering are derived from a variety of tissue sources. Although they share fundamental stem cell characteristics, they exhibit differences in proliferation capacity, secretory profile, and differentiation potential. MSCs sources are broadly categorized into adult tissues (e.g., bone marrow, adipose tissue, dental pulp) and neonatal tissues (e.g., umbilical cord blood, amniotic fluid). Among these, bone marrow-, adipose-, and umbilical cord-derived MSCs are the most frequently utilized in research. Bone marrow-derived MSCs (BM-MSCs) were the first type to be applied clinically and demonstrate pronounced osteogenic and chondrogenic potential, along with strong paracrine functions. Preclinical studies (summarized in Table 2) have shown promising results using BM-MSCs for DFU treatment. Despite their potential, harvesting BM-MSCs is an invasive procedure requiring bone marrow aspiration. Furthermore, both the yield and proliferative capacity of these cells decline with donor age. Additionally, MSCs constitute only 0.001%–0.01% of bone marrow mononuclear cells after density gradient centrifugation.100 Adipose-derived MSCs (AD-MSCs) can be obtained from liposuction procedures, making their harvest relatively straightforward and yielding a substantial number of cells. Adipose tissue affords a higher MSCs yield compared to bone marrow, with approximately 5,000 MSCs obtainable per gram of tissue.100 AD-MSCs secrete a broader spectrum of cytokines and growth factors, including HGF, IL-6, TGF-β1, TNF-α, and VEGF.101 Umbilical cord-derived MSCs (UC-MSCs) are characterized by their high proliferative rate and low immunogenicity. As the umbilical cord is considered medical waste, the procurement of UC-MSCs raises minimal ethical concerns. A limitation, however, is that donor availability is not as abundant as for adult tissue-derived MSCs. A comparative study by Petrenko et al. revealed that UC-MSCs exhibited the highest proliferative activity, whereas BM-MSCs demonstrated superior immunosuppressive activity.102 Heterogeneity of MSCs represents a significant challenge in their clinical translation. And it is a major contributor to inconsistent therapeutic outcomes. The sources of MSC heterogeneity are multifaceted, including inter-donor variability, tissue origin, and culture strategies.103 Researchers have focused on cultivating homogeneous MSCs subpopulations to enhance the stability and predictability of their therapeutic applications. Current strategies to reduce MSCs heterogeneity primarily involve the identification of markers to classify MSCs subpopulations, alongside the use of pooled MSCs, clonal MSCs, primed MSCs, and biomaterial-MSC constructs.104 The development of antibody-conjugated MSCs, which enhances targeting capability and secretory function, offers a novel approach to mitigating heterogeneity.105 These strategies share a common principle: applying external interventions to standardize MSCs function, thereby overcoming the adverse effects of heterogeneity on therapeutic efficacy. Additionally, methods for assessing MSCs heterogeneity have been explored, such as employing fluorescence and label-free quantitative differential phase contrast imaging to extract morphological features and predict immunomodulatory capacity.106 Therefore, standardizing MSCs production and establishing robust potency assays are not merely manufacturing concerns but fundamental prerequisites for ensuring predictable clinical efficacy and overcoming the hurdle of heterogeneity in DFU therapy. Mechanotransduction ECM is a dynamic three-dimensional network that provides structural support and regulates key biological processes. Mechanical forces serve as fundamental regulators of cellular behavior, influencing a wide range of cellular activities such as proliferation, migration, and apoptosis by activating mechanotransduction pathways that convert physical stimuli into biochemical and transcriptional responses.107 The influence of nanofibers topography on MSCs morphology and the associated mechanotransduction pathways are illustrated in Figure 6.Figure 6Schematic illustration of MSCs morphology on electrospun nanofiber scaffolds and the associated mechanotransduction pathways(A) MSCs cultured on random nanofibers exhibit a polygonal morphology with random orientation.(B) MSCs cultured on aligned nanofibers display an elongated, spindle-shaped morphology aligned along the fiber direction.(C) Mechanotransduction pathways (YAP/TAZ, PIEZO1, FAK/ERK) activated by nanofibers.Abbreviations: MSCs, mesenchymal stem cells; COX-2, cyclooxygenase-2; TSG-6, TNF-α-stimulated gene 6; IL-1ra, interleukin-1 receptor antagonist; MCP-1, monocyte chemoattractant protein-1; TGF-β, transforming growth factor β; M-CSF, macrophage colony stimulating factor; HGF, hepatocyte growth factor. All figures in this manuscript are original and were created solely by the authors. Schematic illustration of MSCs morphology on electrospun nanofiber scaffolds and the associated mechanotransduction pathways (A) MSCs cultured on random nanofibers exhibit a polygonal morphology with random orientation. (B) MSCs cultured on aligned nanofibers display an elongated, spindle-shaped morphology aligned along the fiber direction. (C) Mechanotransduction pathways (YAP/TAZ, PIEZO1, FAK/ERK) activated by nanofibers. Abbreviations: MSCs, mesenchymal stem cells; COX-2, cyclooxygenase-2; TSG-6, TNF-α-stimulated gene 6; IL-1ra, interleukin-1 receptor antagonist; MCP-1, monocyte chemoattractant protein-1; TGF-β, transforming growth factor β; M-CSF, macrophage colony stimulating factor; HGF, hepatocyte growth factor. All figures in this manuscript are original and were created solely by the authors. YAP/TAZ, primarily located in the cytoplasm, are transcriptional co-activators and a crucial mechanotransduction pathway. It senses mechanical cues from the ECM and regulate cell proliferation, survival, and ECM remodeling.108 YAP/TAZ is involved in the immunomodulatory effects of aligned nanofiber scaffolds on MSCs, manifested by reduced secretion of pro-inflammatory factors and enhanced expression of M2 macrophage surface markers.109 PIEZO1, a mechanosensitive ion channel, also participates in mechanotransduction and plays an important role in the development of fibrosis. In fibrotic environments, elevated ECM stiffness upregulates Piezo1 expression, activates fibroblasts, and subsequently exacerbates matrix deposition and tissue stiffening.110 However, research by Neda Rashidi’s team revealed that under specific conditions, Piezo1 activation instead reduces collagen accumulation and promotes YAP/TAZ nuclear translocation.111 They suggest that this contradictory phenomenon may stem from cell type-specific functions, diverse microenvironmental signals, and variations in mechanical forces. Furthermore, the relationship between nanofiber alignment design and cell size also influences mechanotransduction. Smaller cells confined within the gaps of aligned fibers exhibit restricted cellular traction due to spatial constraints, whereas larger cells do not. FAK/ERK is another essential route for ECM signal perception and mechanotransduction. During the process of mechanotransduction, conformational changes in integrins and the subsequent activation of the downstream FAK/ERK pathway play a key role in sensing and transmitting various signals.112 Studies have shown that nanofiber scaffolds significantly increase FAK expression in MSCs. Aligned fibers primarily activate the FAK-ERK pathway, while random fibers mainly trigger the ERK signaling pathway.113,114 In summary, nanofiber scaffolds harness key mechanotransduction pathways—such as YAP/TAZ and FAK/ERK—to orchestrate MSCs fate and function. Future research should focus on elucidating the precise molecular mechanisms of these mechanotransduction pathways and their complex crosstalk, thereby enabling more precise manipulation of MSCs behaviors to maximize therapeutic efficacy in DFU repair. Sustained bioactive release As mentioned earlier (paracrine, immunomodulatory, and anti-inflammatory effects), the paracrine function of MSCs is crucial in the wound healing process. Most current research aims to improve delivery strategies to provide a more suitable microenvironment for MSCs, but studies on the mechanisms by which nanofiber scaffolds regulate MSC paracrine signaling are relatively scarce. Research by Ni Su et al. demonstrated that nanofiber scaffolds can promote the secretion of various cytokines from MSCs (e.g., COX-2, TSG-6, iNOS, TGF-β, VEGF, bFGF, and HGF). They also found that fiber morphology and orientation can influence the secretion levels of different cytokines.115 However, this study did not fully elucidate the underlying mechanism, only speculating that nanofiber scaffolds might activate the downstream NF-κB signaling pathway to stimulate MSCs. Atorvastatin, a classic lipid-lowering drug, has been found to promote wound healing, exert anti-inflammatory and pro-angiogenic actions, as well as protect MSCs and enhance their paracrine effects. Based on this, Xiang et al. designed an atorvastatin-loaded fibrous scaffold, which enables the sustained and steady release of atorvastatin and promotes the paracrine function of MSCs.113 The work of Kadir et al. further confirmed that nanofiber scaffolds enhance MSC paracrine signaling. Moreover, different fiber alignments can activate distinct signaling pathways, leading to varied paracrine effects.114 Combined with the previous discussion on mechanotransduction, it is evident that nanofiber scaffolds can enhance the paracrine function of MSCs and increase the expression of various pro-healing cytokines through mechanotransduction. The sustained and localized release of these pro-healing factors from MSC-laden scaffolds is critical to counteract the protracted inflammatory and ischemic signals in the microenvironment of DFU, thereby shifting the wound from a state of chronic stagnation to active regeneration. In the future, the expression levels of cytokines should be considered as one of the key metrics for assessing the quality of scaffold products. Scaffold degradation Natural ECM is primarily degraded by MMPs. MMPs play central roles in numerous biological processes, such as tissue remodeling, wound healing, and angiogenesis, as well as in diseases including atherosclerosis, arthritis, cancer, and tissue ulcers.116 Consequently, the overexpression of MMPs can exacerbate certain pathological processes, including exacerbating inflammation and impeding wound healing in DFU,117 degrading type II collagen leading to cartilage destruction and joint function loss, and degrading the basement membrane and ECM barrier to promote tumor progression and metastasis. Although nanofiber scaffolds can mimic the natural ECM, they are either non-degradable or degrade via hydrolysis. Their degradation rates are predominantly determined by the passive release governed by material crystallinity, hydrophobicity, and the hydrolytic stability of the polymer backbone.118 For instance, the aforementioned PLGA scaffolds exhibit tunable degradation rates. Addressing the non-enzymatic degradability of scaffolds, Wade, R.J et al. designed a protease-sensitive fibrous scaffold, further refining the degradation mechanisms of nanofiber scaffolds.118 According to existing research, the close association between MSCs and MMPs plays a crucial bidirectional regulatory role in tissue repair. MSCs can induce cardiac fibroblasts to secrete MMP-2, significantly reducing collagen deposition and cardiac fibrosis.119 IL-27-induced MSC-derived exosomes promote the expression of MMP-3 in synovial fibroblasts, exacerbating cartilage destruction.120 Human umbilical cord-derived MSCs (hUC-MSCs) may enhance DFU wound healing by reducing MMP-9 expression and increasing MMP-8 expression in the wound tissue.121 Given the critical role of MMP-9 in mediating the anti-fibrotic action of MSCs, MSCs are now being explored for application in anti-fibrotic treatments.122 Furthermore, MSCs not only activate exogenous proMMP-2 and proMMP-13 but also secrete tissue inhibitors of metalloproteinases, thereby bidirectionally regulating the ECM.123 The above findings suggest that MMP functions are significantly regulated by MSCs. The degradation of the vast majority of nanofibrous scaffolds may not be influenced by MSCs, with the exception of protease-sensitive fibrous scaffolds. It is noteworthy that nanofiber scaffolds loaded with MSCs should routinely measure MMPs subtypes and expression levels to assess their actual impact on DFU healing. Prior to the future commercialization of scaffolds, MMPs expression levels should be considered one of the important safety indicators. Additionally, since the raw materials used for scaffold fabrication differ, their hydrolytic properties also vary. Understanding the hydrolytic parameters of various nanofiber scaffolds is essential for determining appropriate dressing change frequencies. Advantages of nanofiber scaffolds A variety of carriers have been employed for the delivery of MSCs; yet, each possesses inherent limitations. While PRF and microneedle systems offer the advantage of protecting MSCs, they are restricted by their single functionality and lack of mechanotransduction to guide orderly cell growth. Hydrogels, despite their excellent cell encapsulation capability, often exhibit insufficient mechanical strength, which becomes a critical drawback in weight-bearing areas such as the foot. dECM, although possessing a biochemical composition closest to native tissue, faces challenges including limited sources, inadequate biomechanical strength, and potential immune responses.124 In contrast, electrospun nanofiber scaffolds demonstrate a core advantage in their highly designable unity of structure and function. Their biomimetic, fibrous topology resembling the native ECM not only enables efficient loading and controlled release of various functional molecules (e.g., antibacterial, anti-inflammatory, and pro-angiogenic) but, more importantly, provides MSCs with essential mechanotransduction and promotes paracrine signaling. This is crucial for inhibiting hypertrophic scarring and achieving high-quality, functional skin regeneration. To address the complex microenvironment of DFU, nanofibrous scaffolds can serve not merely as a physical “shelter” for MSCs but also as a multifunctional platform featuring precise programming, structural support, and mechanotransduction. The limitations of preclinical studies Although the studies summarized in Table 3 consistently demonstrate that electrospun nanofiber scaffolds loaded with MSCs have a favorable effect on DFU wound healing, caution is warranted when interpreting these preclinical data. Substantial heterogeneity across studies limits the comparability of findings and introduces uncertainty for clinical translation. First, in terms of animal model selection, the vast majority of studies have used acute wound models. Although such models are operationally controllable and reproducible, they inadequately replicate the complex wound microenvironment of human DFU. Second, the efficacy assessment metrics are relatively limited. Most studies have used the wound closure rate as the primary outcome measure, but relying solely on this metric makes it difficult to comprehensively evaluate the quality of functional skin regeneration. Ideal wound repair should involve full-thickness functional regeneration of the skin, restoring skin structure, appendages, mechanical properties, and aesthetic appearance. However, these parameters have rarely been systematically assessed in existing studies. Third, a key rationale for scaffold design is to provide a protective microenvironment that enhances MSCs retention and survival within the wound. However, most studies lack systematic evaluation of the fate and function of MSCs in vivo, including critical parameters such as MSCs survival, proliferative capacity, differentiation trajectory, and duration of paracrine activity. Fourth, although most studies have included blank or conventional dressing control groups, few have used advanced dressings (e.g., multifunctional hydrogels, microneedles, silver-containing dressings) as positive controls. This limits a clear assessment of whether the MSC-scaffold strategy outperforms other existing therapies. Finally, DFU is often complicated by bacterial infection and neurological deficits, which significantly impair wound healing and patient outcomes. Most study designs have not specifically addressed infection, nor have they effectively evaluated nerve regeneration or functional recovery. Safety considerations of electrospun scaffolds Beyond the aforementioned limitations in study design, the potential risks associated with the practical application of electrospun nanofibers should not be overlooked. The adverse effects of scaffolds primarily arise from the physicochemical properties of the scaffold materials, the biological effects of their degradation products, residual organic solvents from the fabrication process, and the incorporation of functional additives.125 For instance, PCL is highly hydrophobic, which compromises cell adhesion and delays tissue regeneration. Polyethylene terephthalate exhibits low surface free energy and poor wettability, making it prone to thrombosis and infection.126 With respect to degradation products, biodegradable polymers such as polyurethane and PLGA release acidic byproducts upon ester bond hydrolysis, which may induce inflammatory responses and affect cell viability.127 Risks associated with the fabrication process also warrant attention, as toxic organic solvents (e.g., hexafluoroisopropanol) may persist in scaffolds after volatilization and trigger cytotoxicity or inflammatory reactions.128 Nanomaterials (e.g., silver nanoparticles, and graphene) added to confer antimicrobial or pro-regenerative properties also exhibit cytotoxicity at specific concentrations.129,130 Additionally, scaffold implantation may trigger a foreign body response via immunomodulatory pathways. For instance, the calcium-coated PCL scaffold has been shown to induce macrophage recruitment and VEGF release, leading to neovascularization and fibrotic encapsulation.131 Therefore, the clinical translation of nanofibrous scaffolds necessitates a systematic balance among material design, process control, safety evaluation, and efficacy validation, so as to minimize biological risks and facilitate progression toward clinical application. Selection strategy for materials and MSC sources A wide range of materials is available for fabricating nanofibrous scaffolds, each presenting distinct advantages and limitations. Material choice should be based on an integrated assessment of mechanical support, biofunctionality, and degradation behavior. For instance, PCL offers mechanical stability and slow degradation, making it suitable for load-bearing areas. CS exhibits inherent antibacterial activity and is advantageous in wounds with a high risk of infection. PLGA allows controlled release of bioactive factors, enabling precise modulation of the wound microenvironment. PVA improves hydrophilicity and can facilitate local drug delivery. Similarly, MSCs sources should be selected by evaluating cellular potency, accessibility, and clinical applicability. BM-MSCs are well-documented and represent a reliable option; however, their acquisition requires invasive procedures and yields a limited number of cells per harvest. AD-MSCs are easily accessible and demonstrate strong pro-angiogenic capacity, rendering them appropriate for ischemic wounds. UC-MSCs are characterized by high proliferative activity and potent immunomodulatory functions, properties that render them particularly suitable for inflammation-dominated cases. Therefore, an optimal treatment strategy should match material properties and MSCs functions according to wound characteristics. By integrating pre-functionalized electrospun nanofibers with appropriately selected MSCs, a bioactive system capable of dynamically interacting with the wound microenvironment can be constructed. This approach supports personalized treatment strategies for DFU patients—differentiated by infection status, wound depth, and healing period—and contributes to the achievement of functional wound healing (Table 4).Table 4Selection strategy for materials and MSCs sources based on DFU wound characteristicsDominant wound abnormalityPrimary therapeutic goalRecommended Biomaterial strategyRationale for materialRecommended MSC sourceRationale for MSC selectionSevere ischemia/hypoxiaPromote rapid angiogenesis and oxygen delivery•PLGA fibers loaded with VEGF/bFGF•PVA-based scaffolds to improve hydration•PLGA, tunable degradation allows sustained release of pro-angiogenic factors.•PVA, high hydrophilicity manages exudate and maintains a moist, nutrient-rich environment.AD-MSCsSecrete a robust profile of angiogenic factors (VEGF, HGF, FGF-2), demonstrating superior pro-angiogenic potency in ischemic settings.Persistent infection/biofilmEradicate pathogens and prevent recurrence•CS fibers•CS/AgNP or CS/antibiotic composites•CS, inherent broad-spectrum antimicrobial and antifungal activity disrupts microbial membranes.•Composites, synergistic action enhances bactericidal efficacy and reduces resistance risk.UC-MSCs/BM-MSCsPotent immunomodulatory capacity enhances phagocytic activity of host immune cells and helps resolve infection-associated inflammation.Chronic inflammation (M1 >M2)Reprogram macrophage polarization from M1 to M2 phenotype•PLGA fibers loaded with IL-4, IL-10, or anti-inflammatory drugs (e.g., asiaticoside)•PCL/CS blend scaffolds•Functionalized PLGA, controlled delivery of specific immunomodulatory cues directly targets macrophage signaling.•PCL/CS, CS provides mild anti-inflammatory properties, while PCL ensures structural stability.UC-MSCsExhibit the most potent immunosuppressive and anti-inflammatory paracrine activity, effectively promoting M2 macrophage polarization via TSG-6, PGE2, and EV-mediated mechanisms.Large/deep ulcer with matrix deficiencyProvide mechanical support and enhance granulation tissue formation•PCL-based scaffolds•PCL/gelatin or PCL/collagen blends•PCL, high tensile strength and slow degradation (months to years) prevent scaffold collapse under load.•Blends, natural polymers (gelatin, collagen) significantly improve cell adhesion and bioactivity.BM-MSCs/AD-MSCs•BM-MSCs: high osteogenic/chondrogenic potential aids in structural tissue regeneration.•AD-MSCs: easily accessible in large quantities, suitable for extensive wound coverage.Abbreviation, BM-MSCs, bone marrow-derived mesenchymal stem cells; AD-MSCs, adipose-derived mesenchymal stem cells; UC-MSCs, umbilical cord-derived mesenchymal stem cells; PLGA, poly(lactic-co-glycolic acid); VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor ; PVA, poly(vinyl alcohol); HGF, hepatocyte growth factor; FGF-2, fibroblast growth factor 2; CS, chitosan; AgNP, silver nanoparticles; IL-4, interleukin-4; IL-10, interleukin-10; PCL, poly-ε-caprolactone; TSG-6, tumor necrosis factor-stimulated gene 6; PGE2, prostaglandin E2; EV, extracellular vesicles. Table 4Selection strategy for materials and MSCs sources based on DFU wound characteristicsDominant wound abnormalityPrimary therapeutic goalRecommended Biomaterial strategyRationale for materialRecommended MSC sourceRationale for MSC selectionSevere ischemia/hypoxiaPromote rapid angiogenesis and oxygen delivery•PLGA fibers loaded with VEGF/bFGF•PVA-based scaffolds to improve hydration•PLGA, tunable degradation allows sustained release of pro-angiogenic factors.•PVA, high hydrophilicity manages exudate and maintains a moist, nutrient-rich environment.AD-MSCsSecrete a robust profile of angiogenic factors (VEGF, HGF, FGF-2), demonstrating superior pro-angiogenic potency in ischemic settings.Persistent infection/biofilmEradicate pathogens and prevent recurrence•CS fibers•CS/AgNP or CS/antibiotic composites•CS, inherent broad-spectrum antimicrobial and antifungal activity disrupts microbial membranes.•Composites, synergistic action enhances bactericidal efficacy and reduces resistance risk.UC-MSCs/BM-MSCsPotent immunomodulatory capacity enhances phagocytic activity of host immune cells and helps resolve infection-associated inflammation.Chronic inflammation (M1 >M2)Reprogram macrophage polarization from M1 to M2 phenotype•PLGA fibers loaded with IL-4, IL-10, or anti-inflammatory drugs (e.g., asiaticoside)•PCL/CS blend scaffolds•Functionalized PLGA, controlled delivery of specific immunomodulatory cues directly targets macrophage signaling.•PCL/CS, CS provides mild anti-inflammatory properties, while PCL ensures structural stability.UC-MSCsExhibit the most potent immunosuppressive and anti-inflammatory paracrine activity, effectively promoting M2 macrophage polarization via TSG-6, PGE2, and EV-mediated mechanisms.Large/deep ulcer with matrix deficiencyProvide mechanical support and enhance granulation tissue formation•PCL-based scaffolds•PCL/gelatin or PCL/collagen blends•PCL, high tensile strength and slow degradation (months to years) prevent scaffold collapse under load.•Blends, natural polymers (gelatin, collagen) significantly improve cell adhesion and bioactivity.BM-MSCs/AD-MSCs•BM-MSCs: high osteogenic/chondrogenic potential aids in structural tissue regeneration.•AD-MSCs: easily accessible in large quantities, suitable for extensive wound coverage.Abbreviation, BM-MSCs, bone marrow-derived mesenchymal stem cells; AD-MSCs, adipose-derived mesenchymal stem cells; UC-MSCs, umbilical cord-derived mesenchymal stem cells; PLGA, poly(lactic-co-glycolic acid); VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor ; PVA, poly(vinyl alcohol); HGF, hepatocyte growth factor; FGF-2, fibroblast growth factor 2; CS, chitosan; AgNP, silver nanoparticles; IL-4, interleukin-4; IL-10, interleukin-10; PCL, poly-ε-caprolactone; TSG-6, tumor necrosis factor-stimulated gene 6; PGE2, prostaglandin E2; EV, extracellular vesicles. Selection strategy for materials and MSCs sources based on DFU wound characteristics •PLGA fibers loaded with VEGF/bFGF PLGA fibers loaded with VEGF/bFGF •PVA-based scaffolds to improve hydration PVA-based scaffolds to improve hydration •PLGA, tunable degradation allows sustained release of pro-angiogenic factors. PLGA, tunable degradation allows sustained release of pro-angiogenic factors. •PVA, high hydrophilicity manages exudate and maintains a moist, nutrient-rich environment. PVA, high hydrophilicity manages exudate and maintains a moist, nutrient-rich environment. •CS fibers CS fibers •CS/AgNP or CS/antibiotic composites CS/AgNP or CS/antibiotic composites •CS, inherent broad-spectrum antimicrobial and antifungal activity disrupts microbial membranes. CS, inherent broad-spectrum antimicrobial and antifungal activity disrupts microbial membranes. •Composites, synergistic action enhances bactericidal efficacy and reduces resistance risk. Composites, synergistic action enhances bactericidal efficacy and reduces resistance risk. •PLGA fibers loaded with IL-4, IL-10, or anti-inflammatory drugs (e.g., asiaticoside) PLGA fibers loaded with IL-4, IL-10, or anti-inflammatory drugs (e.g., asiaticoside) •PCL/CS blend scaffolds PCL/CS blend scaffolds •Functionalized PLGA, controlled delivery of specific immunomodulatory cues directly targets macrophage signaling. Functionalized PLGA, controlled delivery of specific immunomodulatory cues directly targets macrophage signaling. •PCL/CS, CS provides mild anti-inflammatory properties, while PCL ensures structural stability. PCL/CS, CS provides mild anti-inflammatory properties, while PCL ensures structural stability. •PCL-based scaffolds PCL-based scaffolds •PCL/gelatin or PCL/collagen blends PCL/gelatin or PCL/collagen blends •PCL, high tensile strength and slow degradation (months to years) prevent scaffold collapse under load. PCL, high tensile strength and slow degradation (months to years) prevent scaffold collapse under load. •Blends, natural polymers (gelatin, collagen) significantly improve cell adhesion and bioactivity. Blends, natural polymers (gelatin, collagen) significantly improve cell adhesion and bioactivity. •BM-MSCs: high osteogenic/chondrogenic potential aids in structural tissue regeneration. BM-MSCs: high osteogenic/chondrogenic potential aids in structural tissue regeneration. •AD-MSCs: easily accessible in large quantities, suitable for extensive wound coverage. AD-MSCs: easily accessible in large quantities, suitable for extensive wound coverage. Abbreviation, BM-MSCs, bone marrow-derived mesenchymal stem cells; AD-MSCs, adipose-derived mesenchymal stem cells; UC-MSCs, umbilical cord-derived mesenchymal stem cells; PLGA, poly(lactic-co-glycolic acid); VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor ; PVA, poly(vinyl alcohol); HGF, hepatocyte growth factor; FGF-2, fibroblast growth factor 2; CS, chitosan; AgNP, silver nanoparticles; IL-4, interleukin-4; IL-10, interleukin-10; PCL, poly-ε-caprolactone; TSG-6, tumor necrosis factor-stimulated gene 6; PGE2, prostaglandin E2; EV, extracellular vesicles. Pathology-guided precision design The preceding sections have reviewed the current state of research on electrospun nanofiber and MSCs combination therapy, and proposed a selection framework for materials and cell sources based on wound phenotypes (Table 4). However, the complexity of DFU arises not only from the marked heterogeneity of clinical presentations, but more fundamentally from the dysregulation of multiple signaling pathways. Therefore, future scaffold design should focus on precisely targeted strategies driven by pathological mechanisms. Studies have shown that key signaling pathways (including NF-κB, PI3K/AKT, TGF-β/Smad, MAPK, Notch, and HIF-1) are dysregulated in diabetic wounds, collectively contributing to the complex microenvironment of DFU.132 In response to this complexity, scaffold design should prioritize targeting the dysregulated signaling pathways. For example, in the field of bone tissue engineering, researchers designed a scaffold that induced the differentiation of MSCs into osteocytes by activating the Smad signaling pathway.133 In another study, a scaffold was designed to activate both the Wnt/β-catenin and Smad3, enhancing the osteogenic differentiation capacity of MSCs.134 Currently, there is limited research on signaling pathway dysregulation in the field of DFU, and future scaffold design may draw insights from other fields. Physical parameters of fibrous scaffolds significantly influence multiple biological functions of MSCs, with signaling pathways such as YAP/TAZ and FAK-ERK playing critical roles in mediating these effects. Based on this, scaffold design should actively guide the biological functions of MSCs through precise modulation of scaffold topology and mechanical properties. For instance, fiber orientation and scaffold pore size can regulate the immunomodulatory phenotype of MSCs; appropriate mechanical stiffness can enhance their paracrine activity; and the incorporation of materials with high affinity for integrin can modulate FAK pathway to promote MSC migration and differentiation.135 Diversified scaffold designs enable preprogramming of MSCs functions to meet the therapeutic demands of the complex wound environment. The pathological status of DFU patients is inherently heterogeneous, and a uniform design is unlikely to satisfy the needs of all patients. In recent years, the development of multi-omics technologies has provided powerful tools for dissecting DFU heterogeneity. Multi-omics analysis enables precise identification of the pathological features and underlying molecular signatures. Based on these findings, multifunctional scaffolds can be rationally designed to co-deliver MSCs along with pro-angiogenic factors (e.g., VEGF), anti-inflammatory agents (e.g., IL-4), or antibacterial components (e.g., silver nanoparticles), thereby achieving functional synergy. This personalized cell-scaffold combination strategy, grounded in molecular mechanisms, offers a promising avenue for precision treatment of DFU. Future perspectives and translational challenges The combination of electrospun nanofiber scaffolds and MSCs demonstrates synergistic therapeutic potential beyond conventional treatments by concurrently addressing the multifaceted pathophysiology of DFU, including chronic inflammation, ischemia, neuropathy, and infection. Although numerous preclinical studies have shown promising results, translating this approach into clinical practice remains challenging. Standardization and personalized customization of nanofiber scaffolds The electrospinning process is highly sensitive to variables such as polymer batch, solvent purity, and ambient conditions, which significantly influence fiber morphology, mechanical integrity, and drug release kinetics. Therefore, establishing rigorous and uniform standards for process parameter control and scalable manufacturing is imperative. Furthermore, the functionalization of scaffolds—whether through surface modification or encapsulation of bioactive molecules—requires careful evaluation to ensure it does not adversely affect MSCs viability, proliferation, paracrine secretion, or differentiation potential. Given the heterogeneity of DFU wounds, future scaffold design should advance toward personalized customization. Specifically, scaffolds with tailored antibacterial, pro-angiogenic, or immunomodulatory functions should be developed based on individual wound characteristics, such as WIfI classification, microbial flora, and inflammatory cytokine profiles. In-depth investigation into the combined therapy in the DFU microenvironment Although MSCs-laden nanofibers have demonstrated efficacy in animal models, the interactions between nanofiber scaffolds and MSCs within the complex human DFU microenvironment, as well as the precise molecular mechanisms through which their combination promotes wound healing, remain to be fully elucidated. Advanced technologies such as single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and proteomics should be employed to systematically analyze changes in gene expression profiles and cellular communication networks of various cell types within DFU wounds—including keratinocytes, fibroblasts, endothelial cells, sensory neurons, and diverse immune cells—following combined therapy intervention. These investigations will provide a solid theoretical foundation for optimizing scaffold design and MSCs pretreatment strategies to maximize therapeutic efficacy. From preclinical models to clinical validation Current evidence is primarily derived from animal models of DFU. Thus, there is a compelling need to validate these therapies in well-designed, controlled clinical trials, rather than focusing solely on the development of novel pro-healing materials. Future clinical studies should prioritize rigorous trial designs, including adequately blinded randomized controlled trials, clearly defined primary and secondary endpoints (e.g., time to complete wound closure, recurrence rate, amputation rate, and quality-of-life measurements), and comprehensive safety monitoring. Furthermore, personalized treatment strategies—such as those conceptually outlined in Table 4—should be explored through stratified clinical trials tailored to different patient subgroups. Conclusion The combination of electrospun nanofibers and MSCs represents a highly promising, multifunctional strategy for DFU treatment, simultaneously addressing infection, ischemia, neuropathy, and chronic inflammation. This review has highlighted not only the individual strengths of each component but also the synergistic potential arising from their integration. Key to this synergy is the active role of the nanofibrous scaffold beyond a mere carrier: it provides mechanical guidance via mechanotransduction pathways and modulates the paracrine profile of MSCs. In the Future, overcoming challenges in standardization, elucidating the complex molecular dialogs at the scaffold-cell-wound interface, and validating efficacy in rigorous clinical trials will be essential to harness the full potential of this innovative approach and improve outcomes for patients with DFU. Acknowledgments This work was supported by the 10.13039/501100001809National Natural Science Foundation of China (grant number 82472566, 82370838), the Health Science and Technology Project of Hubei Province (grant number WJ2025Z007), and the Key Research and Development Program of Hubei Province (grant number 2024BCB039). Author contributions H.D.: writing – review and editing, writing – original draft, and investigation; X.Y.: supervision and funding acquisition; Z.C.: supervision and funding acquisition. Declaration of interests All authors declare no competing interests.